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Abstract
Background: Simvastatin is a widely used medication in cardiac care. Here we evaluate the role of
ATP sensitive potassium (KATP) channels in simvastatin induced renal protection after renal ische-
mia/reperfusion (I/R) injury.
Methods: A total of 81 male Wistar rats, were treated with simvastatin (10 and 20mg/kg/day; ga-
vage, one week). Some groups received glibenclamide (KATP channel inhibitor; 5mg/kg) before
ischemia (45min) and reperfusion (24h). Finally the kidneys were processed for histological analysis
and measurement of biochemical parameters including tissue malondialdehyde (MDA), blood urea
nitrogen (BUN), fractional excretion of sodium (FENa), creatinine clearance rate (CCr) and Bcl2-
associated X protein (Bax) expression.
Results: IR significantly increased serum Cr (p< 0.01) and BUN levels (p< 0.01), elevated FENa
(p<0.01) and tissue MDA (p<0.01), and decreased CCr (p< 0.01) and induced histological damage.
Bax pro-apoptotic protein was upregulated in renal tissue after I/R injury and downregulated in
simvastatin pretreated group. Simvastatin at doses of 10 and 20mg/kg/day significantly reduced se-
rum Cr and BUN levels (p< 0.05 vs. IR group), tissue MDA contents and FENa (p< 0.05 vs. I/R) and
increased CCr (p< 0.05 vs. IR). Renal tissue injury was improved only in simvastatin 20mg/kg/day
group (p< 0.05). Glibenclamide significantly abolished protective effects of simvastatin and in-
creased serum Cr and BUN and FENa and decreased CCr (p< 0.05). It also abolished the effects of
simvastatin on tissue injury and MDA contents and downregulated the Bax protein after IR injury
(p< 0.05).
Conclusion: Opening of KATP channels is essential for simvastatin-induced renal protection
against I/R injury.
Keywords: Creatinine Clearance, KATP channels, Renal ischemia/reperfusion, Simvastatin,
Glibenclamide.
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Introduction
Ischemia/reperfusion (I/R) injury, a
common clinical problem in different
types of renal surgery and transplantation,
is a major cause of acute kidney injury
(AKI) (1,2). Pharmacological modula-
tions to increase kidney tolerance against
ischemic injury would help to reduce the
incidence of early graft dysfunction.
However, successful strategies to moder-
ate renal I/R injury are inadequate and
novel therapies are required (3). Several
mechanisms are involved in renal cell
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damage after I/R injury. Oxidative stress
is one of the pathogenic mechanisms
known to be involved in renal tubular
damage (4). A recent study by Fonseca et
al. revealed that malondialdehyde (MDA)
level one day after transplantation is in-
versely correlated with early graft func-
tion after renal transplantation and its lev-
el 7 days after transplantation is inversely
correlated with 1-year graft survival (5).
MDA is a marker of oxidative stress in
tissue which has been shown to signifi-
cantly increase early after I/R injury (5,
6). Another mechanism which is believed
to be involved in I/R injury is the mito-
chondrial membrane depolarization and
translocation of cytochrome C from mito-
chondria to the cytosol which trigger the
apoptotic death of renal cell (7, 8). Jones
et al. has demonstrated that simvastatin
attenuates membrane depolarization sub-
sequent to oxidative stress by opening
ATP-dependent (K+) (KATP) ion chan-
nels in the mitochondrial membrane.
It has been suggested that the preven-
tion of I/R injury in transplantation set-
tings should be started before organ re-
covery by donor pretreatment (9). Sev-
eral pharmacological agents, including
simvastatin, have been suggested for use
as pretreatment to reduce I/R injury ad-
verse outcomes. Simvastatin is a 3-
Hydroxy-3-methylglutaryl–coenzyme A
(HMG-CoA) reductase inhibitor which
has been widely used in clinical practice
for reduction of serum cholesterol levels
and subsequent risk for coronary events
(10). Recent studies have demonstrated
its protective effects against I/R injury
when used as pretreatment in different
organs including myocardium (11), kid-
ney (12), and spinal cord (13). Studies
have revealed that this effect of simvas-
tatin in cardiac tissue is mediated, at
least in part, by opening KATP ion
channels (11, 14). There are also many
reports on the antioxidant properties of
the simvastatin (15-17). However, un-
derlying mechanisms of renoprotection
against renal I/R injury mediated by
simvastatin has not been completely un-
derstood.
In the current study we investigated
different aspects of renal protection
against renal I/R injury by simvastatin.
We studied changes in the MDA level,
both as a new marker of graft survival
and a marker of antioxidant capacity of
the tissue, after renal I/R injury in rats
pretreated with simvastatin. We also in-
vestigated the potential involvement of
KATP ion channels in the protection and
its effects on apoptotic cell death, as
measured by the ratio of Bcl-2/Bax pro-
tein levels.
Methods
Animals and groups: Experiments
were conducted on male Wistar rats
weighing 210-250 g. The rats were
housed in groups of 9 with food and wa-
ter available, under a 12-hour light-dark
cycle (light 7:00 a.m. to 7:00 p.m.) and
controlled temperature (22 ± 2 ̊C). A to-
tal of 81 rats were used in the present
study and each animal was used only
once. The experimental protocol was
approved by the Ethics Review Commit-
tee for Animal Experimentation of Min-
istry of Health and Medical Education
and in accordance with the NIH Guide
for the Care and Use of Laboratory An-
imals.
The following drugs were adminis-
tered: pentobarbital (45mg/kg, ip, Sig-
ma, St. Louis, MO, USA), simvastatin
(10 and 20 mg/kg, gavage: Sigma, St
Louis, Mo, USA), and glibenclamide (5
mg/kg, ip: non selective KATP channels
blocker, Sigma, St Louis, Mo, USA).
Briefly, for activation of simvastatin 4
mg simvastatin was dissolved in 100μl
ethanol then incubated at 50 Ċ for 2
hours. The pH was brought to 7.0 and
the final concentration of stock solution
was adjusted to 4 mg/ml and kept at 4 Ċ
(18).
Nine experimental groups included: 1)
Sham operated control; 2) SIMV10
(Simvastatin 10mg/kg/day; gavage for 7
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days before sham operation) + sham op-
eration; 3) SIMV20 (Simvastatin
20mg/kg/day for 7 days before sham op-
eration) + sham operation; 4) Untreated
left kidney ischemia (45 min) and reper-
fusion (24 h)  (I/R); 5) SIMV10
(Simvastatin 10mg/kg/day for 7 days be-
fore I/R) + I/R; 6) SIMV20 (Simvastatin
20 mg/kg/day for 7 days before I/R) +
I/R; 7) glibenclamide (5mg/kg i.p. 45
minutes before ischemia) + I/R; 8)
SIMV10 + glibenclamide + I/R; 9)
SIMV20 + glibenclamide + I/R.
Experimental protocol for I/R and re-
nal function measurements: Experi-
mental protocol for induction of renal
I/R injury has been discussed previously
(19). Briefly, 3 weeks before ischemia,
the right kidney was removed through a
small flank incision under general anes-
thesia with Pentobarbital sodium (50
mg/kg, i.p.). For induction of I/R injury,
under general anesthesia, the left renal
artery was exposed and occluded with a
non-traumatic arterial clamp for 45
minutes, then blood flow was re-
established by releasing the clamp and
each rat was placed in a metabolic cage
for 24 hours of reperfusion period. Urine
volume was collected during reperfusion
period for measurement of creatinine
and sodium concentrations. After 24
hours of reperfusion animals were killed
humanely and blood samples were pre-
pared and serum was separated by cen-
trifugation and used for measurement of
serum creatinine (SCr) and blood urea ni-trogen (BUN) and renal functional pa-
rameters.
Creatinine and BUN levels were de-
termined in serum and urine by a Hitachi
multi-analyzer and sodium concentration
was determined using a flame photome-
ter (Hitachi, 205D; Hitachinaka, Japan).
The data were applied for calculation of
creatinine clearance rate (CCr) and frac-tional excretion of sodium (FENa).MDA  measurement: Renal tissue
malondialdehyde (MDA) levels after I/R
or sham operation was determined by
thiobarbituric acid method in which
MDA, as a thiobarbituric acid reactive
substance (TBARS), reacts with thio-
barbituric acid (TBA Sigma, St. Louis,
MO, USA) to produce a red colored
complex that has maximum absorbance
at 532 nm(20). The amount of MDA in
tissue is used as an index of lipid perox-
idation. MDA concentration was calcu-
lated from the intensity of pink color of
the final product at 532 nm (Malondial-
dehyde Assay kit, NWLSS, WA, USA).
Results were expressed as nmol MDA
per gram of wet tissue.
Morphological examination of the kid-
ney: The abdominal cavity was opened
and after minimal dissection both kid-
neys were removed. The kidneys were
divided longitudinally and were pro-
cessed for light microscopic observation.
The kidneys were fixed in phosphate-
buffered 10% formalin and then embed-
ded in paraffin, cut at (4-5μm) and
stained with Hematoxylin and Eosin
(H&E). Prepared sections were graded
for histopathological damage by a his-
tologist in a double blind manner. Twen-
ty fields were read in two consecutive
rows. All proximal tubular profiles pre-
senting each field were counted. The se-
verity of the histological lesions was
graded from 1 to 4 according to the fol-
lowing criteria (19):
0: No signs of necrosis (no damage)
1+ : Necrosis of individual cells.
2+ : Necrosis of all cells in adjacent
proximal convoluted tubules, with sur-
vival of   surrounding tubules.
3+ : Necrosis confined to the distal
third of the proximal convoluted tubule
with a band of necrosis extending across
the inner cortex.
4+ : Necrosis affecting all the three
segments of the proximal convoluted tu-
bule.
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Western blotting
The kidney sections for western blot-
ting were immersed in a lysis buffer (in-
cluding sodium dodecyl sulfate 2.5%,
glycerol 10%, Tris-HCl 62.5mM and pH
6.8) and then placed in a thermomixer at
95° for eight minutes. Then samples
were transferred into freezer at -80 °C
for storage until the time of Western blot
analysis. Before Western blotting, bicin-
choninic acid protein assay was per-
formed to determine protein concentra-
tion (absorbance= 560 nm, Pierce).
Equal amount of protein from each sam-
ple (45 µg) was applied on a 12% sodi-
um dodecyl sulfate polyacrylamide gel.
Electrophoretic separation of proteins
was performed using electrophoresis in
denaturing running buffer system (25
mM Tris, 190mM glycine, 0.1% SDS,
pH 8.5). 50 V electric field was applied
for 5 minutes and then voltage increased
to 150 for 60 minutes. Transfer was at
100 V for 120 minutes at room tempera-
ture in wet transfer system (buffer con-
taining 25mM Tris, 190mM glycine and
20% methanol). Proteins were trans-
ferred onto PVDF membranes, and then
membranes were incubated at 4°C in 0.1
M sodium phosphate buffer (pH= 7.4)
and incubated for 2 h with a 1:3500 dilu-
tion of rabbit polyclonal anti-rat Bcl-2
and Bax antibodies (Abcam: catalog
nos. ab7973 and ab53154, respectively)
in 5% non-fat skimmed milk. HRP-
conjugated Rabbit IgG secondary anti-
body–H&L was used for detection
(Abcam: catalog no. ab7090). ECL
chemiluminescence system (Amersham
Pharmacia Biotech, Braunschweig,
Germany) was used for visualization of
the blots, and the photosensitive film
was developed and used for measure-
ment of optical density.
Statistical analyses
Results for measurement of Cr, BUN,
MDA, CCr and FENa are presented asmeans ± S.E.M. Means of groups were
compared by one-way analysis of vari-
ances (ANOVA) then post-hoc analysis
(Tukey test) was performed for as-
sessing specific group comparisons.
Mann-Whitney U test was used for
comparison of histological data. The
level of statistical significance was set as
p <0.05. Calculations were performed
using the SPSS 14.
Results
Serum creatinine (SCr) and BUN: SCrand BUN levels were normal in sham-
operated groups receiving 10 and 20
mg/kg/day of simvastatin (0.68 ± 0.12
and 0.71 ± 0.1 mg/dl and 10.88 ± 3.82
and 14.35 ± 3.22 mg/dl, respectively).
I/R significantly increased SCr (1.93 ±0.24mg/dl, p<0.01; Fig. 1a) and BUN
Fig. 1: SCr and BUN levels in different groups (a)
SCr and (b) serum BUN was determined in samples
which were collected during the reperfusion period.
All data were shown as mean±SEM. I/R: Ischemia
(45 min) and reperfusion (24 h), SIMV (Simvastatin
10 or 20 mg/kg/day for 7 days), GLi: Glibenclamide
(5mg/kg 45 min before ischemia I.P.). * p<0.05 and
** p<0.01 vs. sham, # p<0.05 vs. I/R, †p<0.05 vs.
SIMV10+I/R and ‡ p<0.05 vs. SIMV20+I/R.
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levels (53.3 ± 7.44mg/dl, p<0.01; Fig.
1b) in comparison with sham group. Pre-
treatment with simvastatin 10 and 20
mg/kg/day significantly reduced SCr andBUN levels (1.37 ± 0.18 and 1.09 ± 0.13
mg/dl: p<0.05 vs. I/R and 35.71 ± 6.5
and 30.62 ± 4.11: p<0.05 vs. I/R; Figure
1).
Although glibenclamide by itself had
no significant effect on SCr and BUNlevels, it abolished the effect of simvas-
tatin 10 and 20 mg/kg/day on decreasing
the SCr and BUN levels (p<0.05).Simvastatin 10 and 20 mg/kg/day
treatment  increased CCr from 0.36 ± 0.1ml/min in I/R group to 0.48±0.13 and
0.84±0.21 ml/min, respectively (p<0.05)
and  decreased FENa from 27±5.62% to
20±3.16% and 12±2.73%, respectively
(p<0.05). However, in groups which re-
ceived glibenclamide, simvastatin could
not produce significant change in CCr orFENa in comparison to the I/R group(Fig. 2a and 2b).
MDA levels and lipid peroxidation:
Renal tissue MDA levels increased after
I/R and reached to 60.44±7.1nmol/gr tis-
sue (p<0.01 vs. sham; Figure 3). Pre-
treatment with both doses of simvastatin
attenuated MDA level (49.5±5.29 and
28.01±4.31 nmol/mg tissue p<0.01)
which was abolished by glibenclamide
treatment 45 min before ischemia
(58.11±6.51 and 53.7±7.02nmol\mg tis-
sue, p<0.05 vs. simvastatin+ I/R treated
groups).
Histological assessment: Results of
histological examinations are shown in
Table 1 and Figures 4 and 5. In sham-
operated groups saline or simvastatin 10
and 20mg/kg/day had no effect on histo-
logical profiles (Figs. 4a, 4b and 4c). I/R
induced moderate to severe histological
damage (p<0.001 vs. sham, Table 1)
with lose of brush border in the main
parts of proximal tubules,  a large num-
ber of cell debris and detached epithelial
structures which obstructed tubules and
led to swelling of the tubules (Fig. 4d).
Treatment with simvastatin (10mg/kg)
could not change renal histology, and
microscopic field similar to the I/R
group was reported by histologists (Fig.
4e). In contrast simvastatin (20mg/kg)
significantly reduced tubular damage
(p<0.05 vs. I/R group and p<0.05 vs.
simvastatin 10mg/kg; Table 1 and Fig.
4f) and restricted cellular debris and
tubular swelling to some parts of studied
fields. When glibenclamide was admin-
istered alone or in combination with
simvastatin 10 or 20 mg/kg group, se-
vere tubular damage were apparent in
prepared slices (p<0.05; Table 1 and
Figs. 5a, 5b and 5c).
Fig. 2. Creatinine clearance rate (CCR: ml/min) and frac-tional excretion of sodium (FENa) in different groups. (a)CCR was calculated from Cr concentrations in urine andserum and urine volume during 24 hours after ischemia.
(b) FENa was calculated from CCr and sodium concentra-tions in urine and serum during 24 hours after ischemia.
All data was shown as mean±SEM. I/R: Ischemia (45
min) and reperfusion (24 h), SIMV (Simvastatin 10 or
20 mg/kg/day for 7 days), GLi: Glibenclamide (5mg/kg
45 min before ischemia I.P.). * p<0.05 and ** p<0.01 vs.
sham, # p<0.05 vs. I/R, †p<0.05 vs. SIMV10+I/R and ‡
p<0.05 vs. SIMV20+I/R.
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Western blot
Western blot analysis revealed that
simvastatin in all applied doses did not
alter the expression of Bcl-2 and Bax
proteins. While I/R injury significantly
altered the expression of these proteins
compared to sham operated group,
simvastatin treatment with doses of 10
and 20mg/kg significantly reduced the
expression of Bax protein while having
no significant effect on Bcl-2 protein
expression. Glibenclamide did not affect
the Bcl-2 and Bax proteins level when
compared to I/R group. In I/R group re-
ceiving simvastatin and glibenclamide,
Bax protein level was increased com-
pared to groups receiving simvastatin
with doses 10 and 20 mg/kg (p<0.05;
Fig. 6). Simvastatin’s effect on Bax pro-
tein level appeared to be dose depend-
ent.
Discussion
In the current study we investigated
the protective effects of the simvastatin
on renal tissue after renal I/R injury. The
results revealed that simvastatin at doses
of 10 and 20mg/kg administered one
week before I/R injury, protected the
kidney against injury and improved re-
nal function, reduced MDA level and
decreased the expression of pro-
apoptotic Bax protein in I/R-injured tis-
sue. It also decreased renal tubular tissue
damage. Glibenclamide prevented these
effects of simvastatin and worsened re-
nal function, decreased tissue antioxi-
dant capacity, increased renal tubular
damage, and reversed the effects of
Table 1. Histological scores obtained from each group and comparison of the severity of tissue damage between
groups
Groups Number (%) of each grade observations Total (%)
0 1 2 3 4
1 Sham 82
(91.1)
7 (7.8) 1 (1.1) - - 90
(100%)
2 SIMV10+Sham 85
(94.4)
5 (5.6) 0 0 0 90
(100%)
3 SIMV20+Sham 79
(87.8)
9 (10) 2 (2.2) 0 0 90
(100%)
4 IR *** 6 (6.6) 17
(18.8)
31
(34.4)
37
(41.0)
2
(2.2)
90
(100%)
5 SIMV10+IR ** 9 (10) 22
(24.5)
27
(30.0)
30
(33.3)
2
(2.2)
90
(100%)
6 SIMV20+IR * # † 18
(20.0)
44
(48.9)
19
(21.1)
8 (8.9) 1
(1.1)
90
(100%)
7 GLi+IR *** 5 (6.25) 8
(10.0)
32
(40.0)
32
(40.0)
3
(3.75)
80
(100%)
8 SIMV10+GLi+IR ***
†
6 (6.7) 18
(20.0)
31
(34.4)
33
(36.7)
2
(2.2)
90
(100%)
9 SIMV20+GLi+IR
***‡
10
(11.1)
24
(26.7)
28
(31.1)
28
(31.1)
0 90
(100%)
Each row shows the number (percent) of total observation of that grade in each group. From any of left kidneys 5 slices were
prepared and graded by two specialist who were blinded about experimental design and groups; Total observation = N of rats in
each group × N of slices from each kidney × 2 pathologist. I/R: Ischemia (45 min) and reperfusion (24 h), SIMV (Simvastatin 10
or 20 mg/kg/day for 7 days), GLi: Glibenclamide (5mg/kg 45 min before ischemia I.P.). Mann-Whitney U test results: * p<0.05,
** p<0.01 and *** p<0.01 vs. sham, # p<0.05 and ##p<0.01 vs. IR, †p<0.05 vs. SIMV10+I/R and ‡ p<0.05 vs. SIMV20+IR.
Number of rats in all groups was 9 except Gli+I/R with 8 rats (One of rats died at the end of reperfusion period).
Fig. 3. MDA contents of renal tissue 24h after ische-
mia in different groups. All data was shown as
mean±SEM. I/R: Ischemia (45 min) and reperfusion
(24 h), SIMV (Simvastatin 10 or 20 mg/kg/day for 7
days), GLi: Glibenclamide (5mg/kg 45 min before
ischemia I.P.). * p<0.05 and ** p<0.01 vs. sham, #
p<0.05 vs. I/R, †p<0.05 vs. SIMV10+I/R and ‡
p<0.05 vs. SIMV20+I/R.
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simvastatin on Bax protein level in I/R-
injured kidney tissue of animals treated
with simvastatin at doses 10 and
20mg/kg and 5mg/kg glibenclamide.
The HMG-CoA reductase inhibitors
(statins), known for their cholesterol
lowering effects, have been tested for
application in the treatment of I/R inju-
ries in various kinds of tissues such as
kidney (12, 21), liver (22-24), heart (11)
and spinal cord (13). In the current study
our data demonstrated that simvastatin
significantly improves outcomes after
renal I/R injury in male Wistar rats. I/R
injury is regularly associated with re-
duced antioxidant capacity of the tissue
(1, 20). In the current study, we ob-
served reduced antioxidant capacity of
Fig. 4. The effect of simvastatin on renal histology after I/R injury. (a) Sham, (b) simvastatin 10 mg/kg/day and (c)
simvastatin 20 mg/kg/day showed normal appearance in most of the slices and marked as grade 0 or 1 in pathological
scoring system. (d) I/R induced moderate to severe histological damage in most slices which is shown by the loss of
brush border in the main parts of proximal tubules, large numbers of cell debris and detached epithelial structures
which obstructed tubules and tubular swelling (white arrows). (e) Simvastatin (10mg/kg/day) could not change I/R
induced renal injury; cellular debris exists in most parts of the studied field with distended tubular spaces (white ar-
rows). (f) Simvastatin (20mg/kg) restricted cellular debris and tubular swelling to some parts of the studied fields;
grade 1 was the frequent feature of slices prepared from this group.
Fig. 5. Renal histology in groups which were treated with (a) glibenclamide alone or in combination with (b) Simvas-
tatin 10 or (c) Simvastatin 20 mg/kg/day. Severe tubular damage was apparent in prepared slices from all of these
groups and all types of tubular damage were apparent in most of the slices (white arrows show tubular swelling, cel-
lular debris and detachment of epithelium).
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the tissue after I/R injury which was im-
proved in groups pretreated with simvas-
tatin. This is consistent with other stud-
ies presenting the data on simvastatin
protection of kidney against oxidative
stress induced injury (25, 26). Tissue
MDA level was significantly increased
after I/R injury in non-treated groups,
while this metabolite was significantly
less in simvastatin treated groups. There
was an inverse correlation between
MDA levels and renal function after I/R
injury. This is consistent with the obser-
vations by Fonseca et al. (5), which
demonstrated the inverse correlation be-
tween MDA levels on day 1 after trans-
plantation and early graft function. Their
study also demonstrated that MDA level
7 days after transplantation is an inde-
pendent predictor of 1-year graft func-
tion. In the current study we were only
able to observe the renal function early
after I/R injury. Other studies are re-
quired for investigating the effects of
simvastatin pretreatment on graft func-
tion for longer times after I/R injury.
Jones et al. reported that simvastatin
protective effects against I/R injury in
isolated neonatal rat cardiac myocytes
are mediated by induction of nitric oxide
synthase (NOS) and KATP channels
(14). In the current study we observed
that administration of 5 mg/kg of
glibenclamide, a non-selective inhibitor
of KATP ion channels, abolished the
beneficial effects of simvastatin on I/R-
injured kidneys. This implies to the role
of KATP ion channels by simvastatin in
the renal protection after I/R injury.
Zhao et al. achieved similar results with
simvastatin pretreatment on cardiac I/R
injury (11). Their study revealed that
simvastatin improved the outcomes after
cardiac I/R injury by opening mitochon-
drial KATP ion channels. Inhibition of
KATP ion channels with simvastatin is
Fig. 6. level of Bax proteins and Bcl-2 in rat kidney tissues. * p<0.01 vs sham, †p<0.01 vs sham, #p<0.05 vs. I/R,
I/R+Gli, SIMV10+Gli+IR and SIMV20+Gli+I/R
I/R: ischemia reperfusion, SIMV10: simvastatin 10 mg/kg, SIMV20: simvastatin 20 mg/kg, Gli: glibenclamide
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associated with the membrane depolari-
zation and influx of Ca2+ ions and de-
crease mitochondrial membrane poten-
tial (14). Coalescence of Ca2+ ions in
the cytosol triggers apoptotic cell death.
This is potentially mediated by calpains,
an intracellular calcium-dependent pro-
tease. This protease is activated in the
presence of Ca2+ ions and mediates a
series of events which result in Bax-
mediated apoptotic cell death (27). As it
has been demonstrated by Ma et al. that
statins suppress calpain activation (28),
we speculated that reduced apoptotic
cell death and renal tissue preservation
is possibly mediated, at least in part, by
this activity of statins. As treatment with
glibenclamide prevent this activity of
statins, it appears that KATP ion chan-
nels are having a role in this signaling
cascade.
Another potential mechanism of in-
creased apoptotic cell death after I/R in-
jury is upregulation of Bax which has
been demonstrated by Jin et al. to be
mediated by p53 transcription factor ac-
tivation. According to their report, p53
activation is mediated by adiponectin
signaling (29). Adiponectin level in-
crease after renal I/R injury (29) and its
level is directly correlated with several
adverse outcomes after renal I/R injury
(30, 31). Also, observations by Rajtík et
al., demonstrated the upregulation of an-
ti-apoptotic Bcl-2 and downregulation of
pro-apoptotic markers to be induced by
simvastatin after myocardial I/R injury
in isolated rat hearts (32). In the current
study we observed upregulation of Bax
after renal I/R-injury which was down-
regulated by pretreatment with simvas-
tatin. Treatment with glibenclamide
abolished the effects of simvastatin on
Bax protein level which indicates the
potential involvement of KATP ion
channels in this effect of simvastatin.
Further experiments are required to un-
cover the relationship between KATP
channel opening by simvastatin and adi-
ponectin expression.
Conclusion
Up to present study, protective effect
of simvastatin against renal I/R injury
has a common feature with its cardio-
protective effect, and both are mediated
by KATP ion channels.
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